Document Detail

Last chance therapies and managed care. Pluralism, fair procedures, and legitimacy.
MedLine Citation:
PMID:  9589291     Owner:  NLM     Status:  MEDLINE    
How can health plans make fair determinations about when "experimental" (and costly) treatments such as high dose chemotherapy with autologous bone marrow transplantation should be covered despite lack of clear clinical consensus about their benefits? Different models for managing "last chance" therapies evolving in some health plans offer promising examples of how issues of fairness and legitimacy in decision-making can be addressed.
N Daniels; J E Sabin
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  The Hastings Center report     Volume:  28     ISSN:  0093-0334     ISO Abbreviation:  Hastings Cent Rep     Publication Date:    1998 Mar-Apr
Date Detail:
Created Date:  1998-07-30     Completed Date:  1998-07-30     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0410447     Medline TA:  Hastings Cent Rep     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  27-41     Citation Subset:  E; IM    
Tufts University, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / therapeutic use*
Bone Marrow Transplantation / economics*
Breast Neoplasms / drug therapy,  therapy*
Combined Modality Therapy
Cost-Benefit Analysis
Cultural Diversity
Decision Making
Ethics, Medical
Government Regulation
Health Services Needs and Demand
Insurance Coverage
Managed Care Programs*
Personal Autonomy
Quality Assurance, Health Care
Resource Allocation
Risk Assessment
Social Responsibility
Therapeutic Human Experimentation
Therapies, Investigational*
Transplantation, Autologous
United States
Reg. No./Substance:
0/Antineoplastic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A defense of the whole-brain concept of death.
Next Document:  Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoid...